{"id":"NCT04773600","sponsor":"Arcutis Biotherapeutics, Inc.","briefTitle":"Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)","officialTitle":"A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects With Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-02-24","primaryCompletion":"2022-09-29","completion":"2022-09-29","firstPosted":"2021-02-26","resultsPosted":"2024-10-04","lastUpdate":"2024-10-04"},"enrollment":683,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis Eczema"],"interventions":[{"type":"DRUG","name":"Roflumilast Cream","otherNames":["ARQ-151"]},{"type":"DRUG","name":"Vehicle cream","otherNames":[]}],"arms":[{"label":"Roflumilast Cream 0.15%","type":"EXPERIMENTAL"},{"label":"Vehicle Cream","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the safety and efficacy of ARQ-151 cream vs vehicle applied once a day for 4 weeks by subjects with atopic dermatitis (eczema). This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 0.15% cream or vehicle is applied once daily (qd) for 4 weeks by participants with atopic dermatitis.","primaryOutcome":{"measure":"Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4","timeFrame":"Week 4","effectByArm":[{"arm":"Roflumilast Cream 0.15%","deltaMin":28.9,"sd":null},{"arm":"Vehicle Cream","deltaMin":12,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":53,"countries":["United States","Canada"]},"refs":{"pmids":["39292443"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":452},"commonTop":[]}}